Financial Snapshot

Revenue
$2.022M
TTM
Gross Margin
31.85%
TTM
Net Earnings
-$6.847M
TTM
Current Assets
Q4 2024
Current Liabilities
Q4 2024
Current Ratio
496.21%
Q4 2024
Total Assets
Q4 2024
Total Liabilities
Q4 2024
Book Value
$11.23M
Q4 2024
Cash
Q4 2024
P/E
-7.056
Nov 29, 2024 EST
Free Cash Flow
-$3.190M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $2.085M $2.080M $1.422M $943.7K $370.7K $245.3K $0.00 $0.00 $0.00
YoY Change 0.27% 46.23% 50.7% 154.61% 51.11%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $2.085M $2.080M $1.422M $943.7K $370.7K $245.3K $0.00 $0.00 $0.00
Cost Of Revenue $1.223M $1.329M $917.8K $582.4K $549.1K $288.3K
Gross Profit $862.1K $750.4K $504.3K $361.3K -$178.5K -$43.01K
Gross Profit Margin 41.34% 36.08% 35.46% 38.29% -48.15% -17.53%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $3.774M $3.916M $4.023M $2.957M $1.791M $3.288M $172.0K $151.3K $400.00
YoY Change -3.64% -2.65% 36.03% 65.12% -45.53% 1812.31% 13.68% 37715.0%
% of Gross Profit 437.72% 521.86% 797.69% 818.46%
Research & Development $1.960M $982.2K $411.4K
YoY Change 99.59% 138.76%
% of Gross Profit 227.4% 130.89% 81.57%
Depreciation & Amortization $287.7K $330.1K $308.7K $160.1K $72.19K $37.01K
YoY Change -12.85% 6.93% 92.83% 121.79% 95.06%
% of Gross Profit 33.37% 44.0% 61.22% 44.31%
Operating Expenses $5.734M $4.898M $4.434M $0.00 $1.791M $3.288M $171.9K $151.3K $400.00
YoY Change 17.06% 10.47% -100.0% -45.53% 1812.32% 13.68% 37715.0%
Operating Profit -$4.872M -$4.475M -$3.930M $361.3K -$1.969M -$3.331M
YoY Change 8.87% 13.88% -1187.65% -118.35% -40.88%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense $75.82K -$8.290K -$118.4K -$258.6K $15.47K
YoY Change -1014.54% -93.0% -54.21% -1771.56%
% of Operating Profit -71.57%
Other Income/Expense, Net -$613.4K $5.226M $6.615M $0.00 -$767.7K
YoY Change -111.74% -21.0% -100.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$5.485M -$4.483M -$6.176M -$2.933M -$2.722M -$3.331M -$2.672M -$151.3K -$400.00
YoY Change 22.35% -27.41% 110.59% 7.76% -18.3% 24.67% 1666.46% 37715.0%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.485M -$4.483M -$6.176M -$2.933M -$2.722M -$3.331M -$2.672M -$151.3K -$400.00
YoY Change 22.35% -27.41% 110.59% 7.76% -18.3% 24.67% 1666.46% 37715.0%
Net Earnings / Revenue -263.04% -215.59% -434.28% -310.78% -734.29% -1358.08%
Basic Earnings Per Share -$0.69 -$0.53 -$0.80
Diluted Earnings Per Share -$0.69 -$0.53 -$778.5K -$435.6K -$430.1K -$533.5K -$476.8K -$24.45K -$123.40

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $492.9K $1.985M $4.892M $152.0K $10.18K $474.7K $0.00 $27.12K $100.00
YoY Change -75.17% -59.41% 3118.55% 1393.03% -97.86% -100.0% 27020.0%
Cash & Equivalents $492.9K $1.985M $4.892M $152.0K $10.18K $474.7K $0.00 $27.12K $100.00
Short-Term Investments
Other Short-Term Assets $211.7K $365.9K $370.5K $20.17K $102.7K $160.5K $2.330K $0.00
YoY Change -42.16% -1.23% -80.37% -35.99% 6788.41%
Inventory $168.6K $229.3K $131.7K $52.85K $0.00 $4.130K $8.050K $0.00
Prepaid Expenses
Receivables $148.7K $113.1K $71.38K $109.4K $12.83K $13.09K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $1.022M $2.694M $5.465M $314.2K $43.18K $590.5K $164.9K $37.73K $330.00
YoY Change -62.07% -50.71% 1639.51% 627.63% -92.69% 258.08% 337.05% 11333.33%
Property, Plant & Equipment $806.3K $960.5K $998.3K $1.077M $120.6K $146.2K
YoY Change -16.05% -3.79% -7.27% 792.43% -17.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.495M $6.763M $7.274M $9.613M $2.155M $2.217M $0.00 $0.00 $0.00
YoY Change -3.95% -7.03% -24.33% 346.18% -2.82%
Total Assets $7.517M $9.456M $12.74M $9.927M $2.198M $2.808M $164.9K $37.73K $330.00
YoY Change
Accounts Payable $680.1K $534.7K $639.5K $940.6K $771.9K $291.8K $12.34K $4.150K $1.200K
YoY Change 27.2% -16.4% -32.01% 21.85% 164.56% 2264.51% 197.35% 245.83%
Accrued Expenses $34.28K $31.29K $19.33K $0.00 $10.05K
YoY Change 9.56% 61.87% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $1.403M $96.57K $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% 1352.34%
Long-Term Debt Due $127.2K $19.74K $14.12K $138.6K $215.0K $40.00K $16.82K $1.580K $900.00
YoY Change 544.28% 39.8% -89.81% -35.52% 437.5% 137.81% 964.56% 75.56%
Total Short-Term Liabilities $999.1K $748.6K $779.3K $2.569M $2.022M $403.0K $43.39K $14.62K $11.11K
YoY Change 33.46% -3.93% -69.66% 27.01% 401.8% 828.81% 196.79% 31.59%
Long-Term Debt $79.83K $100.5K $101.1K $246.9K $0.00 $0.00 $0.00 $0.00 $690.00
YoY Change -20.57% -0.61% -59.04% -100.0%
Other Long-Term Liabilities $0.00 $34.28K
YoY Change -100.0%
Total Long-Term Liabilities $79.83K $134.8K $101.1K $246.9K $0.00 $0.00 $0.00 $0.00 $690.00
YoY Change -40.77% 33.29% -59.04% -100.0%
Total Liabilities $1.079M $883.4K $880.4K $2.815M $2.022M $403.0K $43.39K $14.62K $11.80K
YoY Change 22.13% 0.34% -68.73% 39.22% 401.8% 828.81% 196.79% 23.9%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 7.954M shares 8.460M shares 7.933M shares
Diluted Shares Outstanding 7.954M shares 8.460M shares 7.933M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $48.312 Million

About NutriBand Inc.

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: TALPHERA, INC. Elicio Therapeutics, Inc. Real Brands, Inc. Clever Leaves Holdings Inc. ELITE PHARMACEUTICALS INC /NV/ Processa Pharmaceuticals, Inc. JOHNSON & JOHNSON NVN Liquidation, Inc. REVIVA PHARMACEUTICALS HOLDINGS, INC.